Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer

Journal of Endocrinology

Volumn 221, Issue 2, 2014, Pages 325-336

  Chan, Karen Kar Loen ^a   Leung, Thomas Ho Yin ^a   Chan, David Wai ^a   Wei, Na ^a   Lau, Grace Tak Yi ^a   Liu, Stephanie Si ^a   Siu, Michelle K Y ^a   Ngan, Hextan Yuen Sheung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Estrogen receptors; Hormonal treatment; Ovarian cancer; SERMS

Indexed keywords

AFIMOXIFENE; ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; PROTEIN KINASE B; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE EXPRESSION; HORMONAL THERAPY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; ESTROGEN RECEPTORS; HORMONAL TREATMENT; HUMAN; MCF 7 CELL LINE; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; OVARY TUMOR; TUMOR CELL LINE;

ESTROGEN RECEPTORS; HORMONAL TREATMENT; OVARIAN CANCER; SERMS;

ANIMALS; CELL LINE, TUMOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84903542659     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-13-0500     Document Type: Article

References (47)

1. Argenta PA, Thomas SG, Judson PL, Downs LS Jr, Geller MA, Carson LF, Jonson AL & Ghebre R 2009 A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecologic Oncology 113 205-209. (doi:10.1016/j.ygyno.2009.01.012)
2. Asselin E, Mills GB & Tsang BK 2001 XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Research 61 1862-1868.
3. Attia DM & Ederveen AG 2012 Opposing roles of ERa and ERb in the genesis and progression of adenocarcinoma in the rat ventral prostate. Prostate 72 1013-1022. (doi:10.1002/pros.21507)
4. Bardin A, Hoffmann P, Boulle N, Katsaros D, Vignon F, Pujol P&Lazennec G 2004a Involvement of estrogen receptor b in ovarian carcinogenesis. Cancer Research 64 5861-5869. (doi:10.1158/0008-5472.CAN-04-0552)
5. Bardin A, Boulle N, Lazennec G, Vignon F & Pujol P 2004b Loss of ERb expression as a common step in estrogen-dependent tumor progression. Endocrine-Related Cancer 11 537-551. (doi:10.1677/erc.1.00800)
6. Brandenberger AW, Tee MK & Jaffe RB 1998 Estrogen receptor a (ER-a) and b (ER-b) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-b in neoplastic tissues. Journal of Clinical Endocrinology and Metabolism 83 1025-1028. (doi:10.1210/jcem.83.3.4788)
7. Castiglione F, Taddei A, Rossi Degl'Innocenti D, Buccoliero AM, Bechi P, Garbini F, Chiara FG, Moncini D, Cavallina G, Marascio L et al. 2008 Expression of estrogen receptor b in colon cancer progression. Diagnostic Molecular Pathology 17 231-236. (doi:10.1097/PDM. 0b013e3181656d67)
8. Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN & Ngan HY 2008 Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstetrics and Gynecology 111 144-151. (doi:10.1097/01.AOG.0000296715.07705.e9)
9. Cheng J, Lee EJ, Madison LD & Lazennec G 2004 Expression of estrogen receptor b in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Letters 566 169-172. (doi:10.1016/ j.febslet.2004.04.025)
10. Cristofaro PA, Opal SM, Palardy JE, Parejo NA, Jhung J, Keith JC Jr & Harris HA 2006 WAY-202196, a selective estrogen receptor-β agonist, protects against death in experimental septic shock. Critical Care Medicine 34 2188-2193. (doi:10.1097/01.CCM.0000227173.13497.56)
11. De Stefano I, Zannoni GF, Prisco MG, Fagotti A, Tortorella L, Vizzielli G, Mencaglia L, Scambia G & Gallo D 2011 Cytoplasmic expression of estrogen receptor b (ERb) predicts poor clinical outcome in advanced serous ovarian cancer. Gynecologic Oncology 122 573-579. (doi:10.1016/ j.ygyno.2011.05.025)
12. Drummond AE & Fuller PJ 2010 The importance of ERb signalling in the ovary. Journal of Endocrinology 205 15-23. (doi:10.1677/JOE-09-0379)
13. Foster TC 2012 Role of estrogen receptor a and b expression and signaling on cognitive function during aging. Hippocampus 22 656-669. (doi:10.1002/hipo.20935)
14. Gardell LR, Hyldtoft L,Del Tredici AL, Andersen CB, Fairbairn LC, Lund BW, GustafssonM, Brann MR, Olsson R&Piu F 2008 Differential modulation of inflammatory pain by a selective estrogen receptor b agonist. European Journal of Pharmacology 592 158-159. (doi:10.1016/j.ejphar. 2008.06.107)
15. Grady D, Sawaya GF, Johnson KC, Koltun W,Hess R, Vittinghoff E,Kristof M, Tagliaferri M, Cohen I & Ensrud KE 2009 MF101, a selective estrogen receptor b modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause 16 458-465. (doi:10.1097/gme. 0b013e31818e64dd)
16. Handa RJ,Mani SK & Uht RM 2012 Estrogen receptors and the regulation of neural stress responses. Neuroendocrinology 96 111-118. (doi:10.1159/ 000338397)
17. Hartman J, Lindberg K, Morani A, Inzunza J, Strom A & Gustafsson JA 2006 Estrogen receptor b inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Research 66 11207-11213. (doi:10.1158/ 0008-5472.CAN-06-0017)
18. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O'Neill G et al. 2001 Frequent loss of estrogen receptor-β expression in prostate cancer. Cancer Research 61 5331-5335.
19. Hughes ZA, Liu F, Platt BJ, Dwyer JM, Pulicicchio CM, Zhang G, Schechter LE, Rosenzweig-Lipson S & Day M 2008 WAY-200070, a selective agonist of estrogen receptor b as a potential novel anxiolytic/antidepressant agent. Neuropharmacology 54 1136-1142. (doi:10.1016/j.neuropharm.2008.03.004)
20. Iwao K, Miyoshi Y, Egawa C, Ikeda N & Noguchi S 2000 Quantitative analysis of estrogen receptor-b mRNA and its variants in human breast cancers. International Journal of Cancer 88 733-736. (doi:10.1002/ 1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M)
21. Jones J, Lagasse LD & Karlan BY 1994 Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines. Gynecologic Oncology 55 421-426. (doi:10.1006/gyno.1994.1316)
22. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S & Gustafsson JA 1996 Cloning of a novel receptor expressed in rat prostate and ovary. PNAS 93 5925-5930. (doi:10.1073/pnas.93.12.5925)
23. Langdon SP, Hawkes MM, Lawrie SS, Hawkins RA, Tesdale AL, Crew AJ, Miller WR & Smyth JF 1990 Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. British Journal of Cancer 62 213-216. (doi:10.1038/ bjc.1990.263)
24. Langdon SP, Hirst GL, Miller EP, Hawkins RA, Tesdale AL, Smyth JF & Miller WR 1994 The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. Journal of Steroid Biochemistry and Molecular Biology 50 131-135. (doi:10.1016/0960-0760(94)90019-1)
25. Lau KM, Mok SC & Ho SM 1999 Expression of human estrogen receptor-a and -b, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. PNAS 96 5722-5727. (doi:10.1073/pnas.96.10.5722)
26. Lazennec G, Bresson D, Lucas A, Chauveau C & Vignon F 2001 ERb inhibits proliferation and invasion of breast cancer cells. Endocrinology 142 4120-4130. (doi:10.1210/endo.142.9.8395)
27. Lindgren PR, Cajander S, Backstrom T, Gustafsson JA, Makela S&Olofsson JI 2004 Estrogen and progesterone receptors in ovarian epithelial tumors. Molecular and Cellular Endocrinology 221 97-104. (doi:10.1016/j.mce. 2004.02.020)
28. Mancuso M, Leonardi S, Giardullo P, Pasquali E, Borra F, Stefano ID, Prisco MG, Tanori M, Scambia G, Majo VD et al. 2011 The estrogen receptor β agonist diarylpropionitrile (DPN) inhibits medulloblastoma development via anti-proliferative and pro-apototic pathways. Cancer Letters 308 197-202. (doi:10.1016/j.canlet.2011.05.004)
29. Marzioni M, Torrice A, Saccomanno S, Rychlicki C, Agostinelli L, Pierantonelli I, Rhonnstad P, Trozzi L, Apelqvist T, Gentile R et al. 2012 An oestrogen receptor b-selective agonist exerts anti-neoplastic effects in experimental intrahepatic cholangiocarcinoma. Digestive and Liver Disease 44 134-142. (doi:10.1016/j.dld.2011.06.014)
30. Mohler ML, Narayanan R, Coss CC, Hu K, He Y, Wu Z, Hong SS, Hwang DJ, Miller DD & Dalton JT 2010 Estrogen receptor β selective nonsteroidal estrogens: seeking clinical indications. Expert Opinion on Therapeutic Patents 20 507-534. (doi:10.1517/13543771003657164)
31. O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF & Langdon SP 2005 Estrogen receptor-α mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocrine-Related Cancer 12 851-866. (doi:10.1677/erc.1.01039)
32. Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstathiou E, Grimani I, Hamilos G, Zorzou M & Dimopoulos MA 2004 Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 66 112-117. (doi:10.1159/000077436)
33. Perez-Gracia JL & Carrasco EM 2002 Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecologic Oncology 84 201-209. (doi:10.1006/gyno.2001.6489)
34. Sareddy GR, Nair BC, Gonugunta VK, Zhang QG, Brenner A, Brann DW, Tekmal RR & Vadlamudi RK 2012 Therapeutic significance of estrogen receptor β agonists in gliomas. Molecular Cancer Therapeutics 11 1174-1182. (doi:10.1158/1535-7163.MCT-11-0960)
35. Sasaki H, Sheng Y, Kotsuji F & Tsang BK 2000 Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Research 60 5659-5666.
36. Siegel R, Ward E, Brawley O & Jemal A 2011 Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: A Cancer Journal for Clinicians 2011 212-236. (doi:10.3322/caac.20121)
37. Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K, Lansdown MR, Parkes AT, Hanby AM, Markham AF et al. 2003 Reduced expression of oestrogen receptor β in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. Journal of Pathology 201 213-220. (doi:10.1002/path.1436)
38. Stovall DW & Pinkerton JV 2009 MF-101, an estrogen receptor b agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women. Current Opinion in Investigational Drugs 10 365-371.
39. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J & Gustafsson JA 2004 Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D.[erratum appears in Proc Natl Acad Sci U S A. 2006 May 23;103(21):8298]. PNAS 101 1566-1571. (doi:10.1073/ pnas.0308319100)
40. Sun J, Ma X, Chen YX, Rayner K, Hibbert B, McNulty M, Dhaliwal B, Simard T, Ramirez D & O'Brien E 2011 Attenuation of atherogenesis via the anti-inflammatory effects of the selective estrogen receptor β modulator 8β-VE2. Journal of Cardiovascular Pharmacology 58 399-405. (doi:10.1097/FJC.0b013e318226bd16)
41. Suzuki T, Miki Y, Ohuchi N & Sasano H 2008 Intratumoral estrogen production in breast carcinoma: significance of aromatase. Breast Cancer 15 270-277. (doi:10.1007/s12282-008-0062-z)
42. Treeck O, Wackwitz B, Haus U & Ortmann O 2006 Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecologic Oncology 102 292-299. (doi:10.1016/j.ygyno.2005.12.019)
43. Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G & Ortmann O 2007 Estrogen receptor β1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. Journal of Endocrinology 193 421-433. (doi:10.1677/ JOE-07-0087)
44. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S,Warner M & Gustafsson JA 2001 A role for estrogen receptor β in the regulation of growth of the ventral prostate. PNAS 98 6330-6335. (doi:10.1073/pnas.111150898)
45. Williams C, Simera I & Bryant A 2010 Tamoxifen for relapse of ovarian cancer. Cochrane Database of Systematic Reviews Issue 3. CD001034. (doi:10.1002/14651858.CD001034.pub2)
46. Zhou M, Higo H & Cai Y 2010 Inhibition of hepatoma 22 tumor by liquiritigenin. Phytotherapy Research 24 827-833. (doi:10.1002/ ptr.3194)
47. Zhu J, Hua K, Sun H, Yu Y, Jin H & Feng Y 2011 Re-expression of estrogen receptor β inhibits the proliferation and migration of ovarian clear cell adenocarcinoma cells. Oncology Reports 26 1497-1503. (doi:10.3892/or. 2011.1430)